Gioia Colafigli

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

Nicola Polverelli, Massimo Breccia, Giulia Benevolo et al. · American Journal of Hematology · 2016 · 87 citations · Full text

Immunodeficiencies, Infectious Events, Clinical Mycology +21

Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients

Massimo Breccia, Maria Stefania De Propris, Clara Minotti et al. · Leukemia Research · 2013 · 32 citations

Hematological Malignancy, Aberrant Phenotypic Expression, Medicine +7

Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population

Massimo Breccia, Paola Finsinger, Giuseppina Loglisci et al. · Annals of Hematology · 2012 · 32 citations

Hematological Malignancy, Single-institution Patient Population, Hematology +5

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib

Massimo Breccia, Matteo Molica, Gioia Colafigli et al. · Oncotarget · 2017 · 25 citations · Full text

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events

Matteo Molica, Emilia Scalzulli, Gioia Colafigli et al. · Annals of Hematology · 2018 · 25 citations

Hemodialysis, Urology, Renal Function +10